title: Nano dot technology enters clinical trials.
authors.forename: Roberta
authors.initials: R
authors.lastname: Friedman
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077608:Aprepitant; D002986:Clinical Trials as Topic; D003102:Colloids; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage* / Q000494:pharmacology; D006046:Gold; D006801:Humans; D008546:Melanoma, Experimental / Q000188:drug therapy; D009025:Morpholines / Q000008:administration & dosage; D053758:Nanoparticles / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D036103:Nanotechnology / Q000639:trends*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D012822:Silicon Dioxide
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D003102:Colloids; D004337:Drug Carriers; D009025:Morpholines; D000077608:Aprepitant; D011092:Polyethylene Glycols; D006046:Gold; D012822:Silicon Dioxide